Semax
Last reviewed September 26, 2026
Semax is a synthetic fragment derived from ACTH, modified so it carries no corticotropic activity. Research examines its role in mental clarity, focus, and cognitive resilience.
Mechanism of action
Research investigates Semax for its influence on brain-derived neurotrophic factor expression and on the dopaminergic and serotonergic systems associated with attention.
- Neurotrophic SupportStudied for a role in BDNF signaling, associated with neural adaptability and resilience.
- Attention PathwaysExplored in research on focus and sustained attention, without the hormonal activity of its parent sequence.
- Route studied
- Subcutaneous
- Research status
- Early clinical
Semax has been examined in animal models of stroke and spinal cord injury and in small human studies, including a clinical trial in patients with ischemic stroke and brain network imaging research, but large-scale trial data are not available.
What the research covers
What research examines
- Recovery after experimental ischemic stroke in rats
- Outcomes in patients at different stages of ischemic stroke
- BDNF and neurotrophic signaling
- Brain network activity, including the default mode network
- Functional recovery after spinal cord injury in mice
- Attention and focus pathways
Reported effects in studies
- Human safety data are limited
- Adverse events are not summarized in the cited studies
- Described as an ACTH-derived fragment modified to lack corticotropic activity
- Long-term safety has not been established in large controlled trials
What research protocols have used
Research protocols have used 1–2 mg per administration, once daily (morning), in 4-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorResearched alongside
Cited research
- [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018 · Clinical trial · PubMed 29798983
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.
BMC genomics · 2014 · PubMed 24661604
- ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
Biomedicines · 2024 · PubMed 39767736
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology · 2025 · PubMed 40692165
- Effects of Semax on the Default Mode Network of the Brain.
Bulletin of experimental biology and medicine · 2018 · PubMed 30225715
Questions about Semax
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH), described in the literature as a synthetic analog of ACTH(4-10). It has been modified so that it does not carry the corticotropic, or hormone-releasing, activity of its parent sequence. Research has examined Semax in the context of mental clarity, focus, cognitive resilience and neuroprotection, including animal models of stroke and spinal cord injury.
Research has investigated Semax for its influence on brain-derived neurotrophic factor (BDNF) expression, a signaling pathway associated with neural adaptability and resilience. It has also been studied in relation to dopaminergic and serotonergic systems linked to attention. Genome-wide studies in rats with focal brain ischemia reported changes in the expression of genes related to immune and vascular systems, and one mouse study linked its effects after spinal cord injury to the μ opioid receptor gene Oprm1.
Published work has examined Semax in rat models of experimental stroke, where ACTH-like peptides were reported to shift brain gene expression profiles disrupted by ischemia. A clinical trial evaluated Semax in patients at different stages of ischemic stroke. Imaging studies have explored its effects on the brain's default mode network and functional connectivity, and a 2025 mouse study examined functional recovery after spinal cord injury. Early evidence is promising but not definitive.
Human safety data on Semax are limited, and adverse events are not summarized in the cited studies. The peptide is described as a modified ACTH fragment lacking corticotropic activity, meaning it is not expected to act on the hormonal pathways of its parent sequence, but this has not been confirmed through large, long-term controlled trials. Much of the available research comes from animal models and relatively small human studies.
Research protocols have used 1–2 mg per administration by the subcutaneous route, once daily in the morning, in 4-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference. Semax is supplied for laboratory research use only.
Ask about Semax
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
Semax at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Cognition
$89.00









